{name}
{subtitle}
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~67 mi. (Santander, Spain, +144 more cities)
facility
Hospital Universitario Marques de Valdecilla ( Site 1501)
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
city
~67 mi. (Santander, Spain, +45 more cities)
facility
Hospital Universitario Marques de Valdecilla ( Site 1602)
drug
cisplatin, +5 more drugs
drug type
chemotherapy, +2 more types
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
city
~67 mi. (Santander, Spain, +52 more cities)
facility
Hospital Universitario Marques de Valdecilla; Servicio de Hematologia
drug
gemcitabine, +4 more drugs
drug type
chemotherapy, +1 more type
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
city
~67 mi. (Santander, Spain, +54 more cities)
facility
Hospital Unversitario Marques de Valdecilla /ID# 229354
drug
carfilzomib, +4 more drugs
drug type
chemotherapy, +3 more types
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
city
~67 mi. (Santander, Spain, +55 more cities)
facility
Hospital Universitario Marqués de Valdecilla (Adults and Pediatrics)
drug type
cellular therapy, +1 more type